Schering AG Sees Betaseron Pricing Flexibility Given Premium On Tysabri
This article was originally published in The Pink Sheet Daily
Executive Summary
Betaseron price increase in December still puts multiple sclerosis therapy at 30% discount to Tysabri (formerly Antegren) based on the wholesale acquisition cost. Betaseron global sales reach $1 bil. in 2004.